Gopika Banker, DO
Nephrology · Voorhees, NJNPI 1649460189
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,769 of the $10,533 with a category attached, or 73.8%. 35 manufacturers reported payments, led by Otsuka Pharmaceutical Development & Commercialization, Inc. at 27.1% of the total. Reporting peaked in 2024 at $3,782 and has fallen 77.5% since, to $850 in 2025. Among nephrology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 272 payments — averaging $38.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- Vifor Pharma, Inc.$1K
- Bayer$705
- OPKO Pharmaceuticals, LLC$664
- Bard Peripheral Vascular, Inc.$623
- AstraZeneca$581
- plus $4K from 29 others
What the payments were for
- Consulting fees$2,70026%
- Food & beverage$7,76974%
- Education$631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $2,850 |
| Vifor Pharma, Inc. | 32 | $1,160 |
| Bayer | 14 | $705 |
| OPKO Pharmaceuticals, LLC | 26 | $664 |
| Bard Peripheral Vascular, Inc. | 5 | $623 |
| AstraZeneca | 26 | $581 |
| Otsuka America Pharmaceutical, Inc. | 20 | $540 |
| Akebia Therapeutics Inc | 17 | $434 |
| Fresenius USA Marketing, Inc. | 23 | $419 |
| Aurinia Pharma U.S., Inc. | 11 | $322 |
| Daiichi Sankyo Inc. | 15 | $313 |
| GSK | 6 | $298 |
| Amgen(2 entities) | 12 | $219 |
| Calliditas Therapeutics US Inc. | 6 | $192 |
| Medtronic | 1 | $156 |
| Baxter Healthcare | 1 | $149 |
| Ardelyx, Inc. | 6 | $130 |
| Sanofi | 4 | $98 |
| Travere Therapeutics, Inc. | 9 | $90 |
| Nxstage Medical, Inc. | 3 | $79 |
| Xeris Pharmaceuticals, Inc. | 5 | $71 |
| Boehringer Ingelheim | 4 | $70 |
| Strongbridge US Inc. | 3 | $51 |
| Ultragenyx Pharmaceutical Inc. | 3 | $49 |
| Mallinckrodt Enterprises LLC | 3 | $42 |
| ANI Pharmaceuticals, Inc. | 2 | $41 |
| Novo Nordisk | 1 | $34 |
| Mallinckrodt Hospital Products Inc. | 2 | $33 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Novartis | 1 | $20 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,533 in reported general payments places this provider in the 90th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 63 | $53,640 |
| LokelmaSodium Zirconium Cyclosilicate | 26 | $44,128 |
| AuryxiaFerric Citrate | 20 | $32,951 |
| Sevelamer Carbonate | 19 | $3,863 |
| Calcitriol | 82 | $2,219 |
| Nifedipine ErNifedipine | 25 | $1,503 |
| Febuxostat | 12 | $1,314 |
| Losartan Potassium | 104 | $702 |
| Hydralazine Hcl | 32 | $558 |
| Allopurinol | 67 | $528 |
| Potassium Chloride | 19 | $514 |
| Gentamicin Sulfate | 16 | $439 |
| Lisinopril | 57 | $434 |
| Spironolactone | 16 | $433 |
| Bumetanide | 18 | $350 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $581 | $97,76889 claims |
| Akebia Therapeutics IncAuryxia | $434 | $32,95120 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $41 | $19715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Voorhees
- Carmen Canals-NavasVoorhees$12K
- Nitesh PatelVoorhees$11K
- Anthony BrownVoorhees$8K
- Gerardo VaralloVoorhees$8K
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Harry DounisNeptune$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.